TSC-100/TSC-101 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of TSC-100/TSC-101’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for TSC-100/TSC-101 is expected to reach an annual total of $28 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

TSC-100/TSC-101 Overview

TSC-100 is under development for the treatment of blood cancers like acute myelocytic Leukemia, acute lymphocytic leukemia and myelodysplastic syndrome in patients receiving hematopoietic stem cell transplant therapy with the goal of preventing relapse, a high unmet need in this setting. It acts by targeting HA-1 antigen. The therapeutic candidate comprises of T cells engineered to express a TCR of interest which are mixed with a genome-wide library of target cell. The drug candidate is developed based on the TScan platform technology. It is administered by intravenous route.

TScan Therapeutics Overview

TScan Therapeutics (TCR) provides life-changing T cell therapies for patients. It is headquartered in Boston, Massachusetts, the US.

The company reported revenues of (US Dollars) US$10.1 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$1.1 million in FY2020. The operating loss of the company was US$48.6 million in FY2021, compared to an operating loss of US$26.2 million in FY2020. The net loss of the company was US$48.6 million in FY2021, compared to a net loss of US$26.1 million in FY2020. The company reported revenues of US$3.4 million for the third quarter ended September 2022, a decrease of 17.1% over the previous quarter.

For a complete picture of TSC-100/TSC-101’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.